(Q45886610)

English

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

R Ljung

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

F A Karim

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

K Saxena

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

T Suzuki

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

P Arkhammar

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

A Rosholm

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

P Giangrande

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

Pioneer™1 Investigators

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

1260-1268

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

Effect of glycoPEGylation on factor VIIa binding and internalization

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Pharmacokinetic consequences of pegylation

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Overview of the human pharmacokinetics of recombinant activated factor VII.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12237

21 January 2018

Identifiers

10.1111/JTH.12237

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23578227

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45886610&oldid=2144459679"